Fexofenadine

Drug Profile

Fexofenadine

Alternative Names: Allegra; Allegra-D; Fexohf-1-96; MDL 16455; MDL 16455A; Telfast; Telfast 120; Telfast 180; TelfastPaediatric; Terfenadine acid metabolite; Terfenadine carboxylate

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Acetic acids; Antiallergics; Benzhydryl compounds; Nonsedating antihistamines; Piperidines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atopic dermatitis; Dermatitis; Perennial allergic rhinitis; Pruritus; Seasonal allergic rhinitis; Urticaria
  • Discontinued Asthma

Most Recent Events

  • 26 Jul 2012 Preregistration for Atopic dermatitis (dry syrup) in Japan (PO)
  • 26 Jul 2012 Preregistration for Perennial allergic rhinitis (dry syrup) in Japan (PO)
  • 11 Mar 2011 The Allegra® OTC family of allergy medication products launched in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top